Jeffrey Del - Nov 11, 2022 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Commercial Officer
Signature
/s/ Jeffrey Del Carmen
Stock symbol
CPRX
Transactions as of
Nov 11, 2022
Transactions value $
-$1,855,584
Form type
4
Date filed
11/15/2022, 04:00 PM
Previous filing
Aug 22, 2022
Next filing
Dec 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $343K +120K $2.86* 120K Nov 11, 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$1.95M -120K -100% $16.23 0 Nov 11, 2022 Direct F2
transaction CPRX Common stock, par value $0.001 per share Options Exercise $42.6K +19K $2.24* 19K Nov 11, 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$294K -19K -100% $15.46 0 Nov 11, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -120K -16.06% $0.00 627K Nov 11, 2022 Common Stock 120K $2.86 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -19K -3.03% $0.00 608K Nov 11, 2022 Common Stock 19K $2.24 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold for personal reasons and does not relate to any disagreements with the Company. Mr. Del Carmen remains an officer of the Company.
F2 Shares were sold in various lots from $15.87 to $16.44 per share. The price listed represents a weighted average price for the shares sold.
F3 Shares were sold in various lots from $15.25 to $15.78 per share. The price listed represents a weighted average price for the shares sold.
F4 Options vested in four annual tranches beginning on August 6, 2019.
F5 Options vested in three annual tranches beginning on December 19, 2019.